Treatment with adalimumab in patients with chronic inflammatory rheumatic diseases: a study of treatment trajectories on a patient level in routine care.

Imke Redeker,Stefan Moustakis,Styliani Tsiami,Xenofon Baraliakos,Ioana Andreica,Bjoern Buehring,Jürgen Braun,Uta Kiltz

Therapeutic advances in musculoskeletal disease（2023）

引用 0|浏览11

暂无评分

摘要

Our results indicated that three of four patients continue biosimilar ADA over 2 years with lower risks of withdrawal for male sex, older age, longer prior duration on originator ADA and originator ADA as first bDMARD.

查看译文

关键词

chronic inflammatory rheumatic diseases,adalimumab,treatment trajectories,patients

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要